Profile data is unavailable for this security.
About the company
Aldeyra Therapeutics, Inc. is a biotechnology company, which is engaged in discovering therapies designed to treat immune-mediated diseases. The Company's product candidates include reactive aldehyde species (RASP) modulators ADX-629, ADX-246, ADX-248, and chemically related molecules for the treatment of systemic and retinal immune-mediated diseases. Its pre-commercial product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the treatment of proliferative vitreoretinopathy and retinitis pigmentosa. Its ADX-629, is an orally administered RASP modulator in clinical development for atopic dermatitis, idiopathic nephrotic syndrome, moderate alcohol-associated hepatitis, chronic cough, and Sjogren-Larsson Syndrome. Its preclinical RASP platform includes ADX-246 and ADX-248 in development for metabolic, retinal diseases and systemic inflammatory diseases.
- Revenue in USD (TTM)0.00
- Net income in USD-30.01m
- Incorporated2004
- Employees10.00
- LocationAldeyra Therapeutics Inc131 HARTWELL AVENUE, SUITE 320LEXINGTON 02421United StatesUSA
- Phone+1 (781) 761-4904
- Fax+1 (302) 636-5454
- Websitehttps://www.aldeyra.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Fractyl Health Inc | 148.00k | -83.16m | 226.07m | 102.00 | -- | 2.69 | -- | 1,527.52 | -1.73 | -1.73 | 0.0031 | 1.76 | -- | -- | -- | 1,450.98 | -- | -- | -- | -- | 37.16 | -- | -46,270.95 | -- | 9.37 | -5.10 | 0.2542 | -- | -- | -- | -48.15 | -- | -- | -- |
bluebird bio Inc | 21.73m | -91.17m | 232.23m | 323.00 | -- | 0.5867 | -- | 10.69 | -0.7446 | -0.7446 | 0.2139 | 2.08 | 0.0383 | -- | -- | 67,263.16 | -16.08 | -33.02 | -21.50 | -37.14 | -10.08 | 19.44 | -419.62 | -4,044.31 | 1.42 | -- | 0.00 | -- | -1.77 | -36.71 | 52.62 | -- | -26.66 | -- |
Acrivon Therapeutics Inc | 0.00 | -64.12m | 237.44m | 58.00 | -- | 1.61 | -- | -- | -2.88 | -2.88 | 0.00 | 4.77 | 0.00 | -- | -- | 0.00 | -44.11 | -- | -46.46 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -93.76 | -- | -- | -- |
Rezolute Inc | 0.00 | -58.21m | 238.42m | 51.00 | -- | 2.63 | -- | -- | -1.14 | -1.14 | 0.00 | 1.77 | 0.00 | -- | -- | 0.00 | -52.46 | -58.48 | -55.28 | -63.38 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -26.13 | -- | 92.29 | -- |
Caribou Biosciences Inc | 33.40m | -115.26m | 238.44m | 158.00 | -- | 0.6946 | -- | 7.14 | -1.45 | -1.45 | 0.4136 | 3.80 | 0.0886 | -- | 11.68 | 211,417.70 | -30.56 | -- | -33.02 | -- | -- | -- | -345.05 | -- | -- | -- | 0.00 | -- | 148.91 | -- | -2.66 | -- | -- | -- |
Aldeyra Therapeutics Inc | 0.00 | -30.01m | 241.82m | 10.00 | -- | 2.13 | -- | -- | -0.5080 | -0.5080 | 0.00 | 1.91 | 0.00 | -- | -- | 0.00 | -19.39 | -36.79 | -22.08 | -40.77 | -- | -- | -- | -- | -- | -- | 0.1182 | -- | -- | -- | 39.47 | -- | -- | -- |
Codexis Inc | 74.23m | -65.13m | 242.72m | 174.00 | -- | 3.06 | -- | 3.27 | -0.9412 | -0.9412 | 1.07 | 1.12 | 0.4039 | 5.92 | 4.34 | 426,632.20 | -35.43 | -17.13 | -43.38 | -20.23 | 82.29 | 77.29 | -87.73 | -37.04 | 3.63 | -- | 0.2617 | -- | -49.39 | 2.97 | -126.96 | -- | 9.80 | -- |
2Seventy Bio Inc | 71.20m | -223.22m | 245.20m | 274.00 | -- | 1.18 | -- | 3.44 | -4.34 | -4.34 | 1.39 | 4.04 | 0.1136 | -- | 2.68 | 259,857.70 | -35.62 | -- | -40.00 | -- | 77.68 | 91.76 | -313.51 | -223.57 | -- | -- | 0.00 | -- | 9.72 | 12.96 | 14.39 | -- | -22.88 | -- |
Gossamer Bio Inc | 0.00 | -172.58m | 246.58m | 135.00 | -- | 9.23 | -- | -- | -1.05 | -1.05 | 0.00 | 0.1181 | 0.00 | -- | -- | 0.00 | -72.02 | -57.43 | -85.67 | -64.38 | -- | -- | -- | -- | -- | -14.73 | 0.8854 | -- | -- | -- | 21.61 | -- | -- | -- |
Design Therapeutics Inc | 0.00 | -58.67m | 251.97m | 57.00 | -- | 0.9347 | -- | -- | -1.05 | -1.05 | 0.00 | 4.77 | 0.00 | -- | -- | 0.00 | -19.44 | -- | -19.98 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -5.61 | -- | -- | -- |
ESSA Pharma Inc | 0.00 | -27.73m | 252.87m | 50.00 | -- | 1.89 | -- | -- | -0.6282 | -0.6282 | 0.00 | 3.01 | 0.00 | -- | -- | 0.00 | -18.71 | -23.01 | -19.12 | -23.67 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 24.27 | -- | -- | -- |
Century Therapeutics Inc | 1.37m | -133.47m | 253.50m | 152.00 | -- | 1.09 | -- | 185.04 | -2.22 | -2.22 | 0.0227 | 2.74 | 0.0034 | -- | -- | 9,013.16 | -33.17 | -- | -35.08 | -- | -- | -- | -9,742.41 | -- | -- | -- | 0.00 | -- | -57.01 | -- | -4.38 | -- | -- | -- |
Tectonic Therapeutic Inc | 0.00 | 30.31m | 255.35m | 13.00 | 2.09 | 0.7296 | 8.35 | -- | 8.28 | 8.28 | 0.00 | 23.75 | 0.00 | -- | -- | 0.00 | 34.57 | -45.22 | 38.47 | -49.14 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 111.48 | -- | -66.27 | -- |
Holder | Shares | % Held |
---|---|---|
Perceptive Advisors LLCas of 05 Apr 2024 | 9.28m | 15.61% |
Knoll Capital Management LPas of 31 Mar 2024 | 5.48m | 9.22% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 3.78m | 6.36% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 3.08m | 5.18% |
Kennedy Capital Management LLCas of 31 Mar 2024 | 1.32m | 2.22% |
Geode Capital Management LLCas of 31 Mar 2024 | 1.03m | 1.73% |
Eagle Asset Management, Inc.as of 31 Mar 2024 | 967.82k | 1.63% |
Verition Fund Management LLCas of 31 Mar 2024 | 940.40k | 1.58% |
SSgA Funds Management, Inc.as of 31 Mar 2024 | 939.57k | 1.58% |
Dimensional Fund Advisors LPas of 31 Mar 2024 | 816.72k | 1.38% |